-
Something wrong with this record ?
Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium
E. Clemens, MM. van den Heuvel-Eibrink, RL. Mulder, LCM. Kremer, MM. Hudson, R. Skinner, LS. Constine, JK. Bass, CE. Kuehni, T. Langer, EC. van Dalen, E. Bardi, NX. Bonne, PR. Brock, B. Brooks, B. Carleton, E. Caron, KW. Chang, K. Johnston, K....
Language English Country Great Britain
Document type Journal Article, Practice Guideline, Research Support, Non-U.S. Gov't, Review
Grant support
P30 CA014089
NCI NIH HHS - United States
P30 CA021765
NCI NIH HHS - United States
U10 CA180886
NCI NIH HHS - United States
NLK
ProQuest Central
from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest)
from 2000-09-01 to 2 months ago
Public Health Database (ProQuest)
from 2000-09-01 to 2 months ago
- MeSH
- Child MeSH
- Cranial Irradiation adverse effects MeSH
- Humans MeSH
- Evidence-Based Medicine MeSH
- Adolescent MeSH
- Young Adult MeSH
- Neoplasms drug therapy radiotherapy MeSH
- Ototoxicity diagnosis etiology prevention & control therapy MeSH
- Delivery of Health Care standards MeSH
- Cancer Survivors * statistics & numerical data MeSH
- Antineoplastic Agents adverse effects therapeutic use MeSH
- Platinum Compounds adverse effects MeSH
- Population Surveillance MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Practice Guideline MeSH
Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
Audiology and Speech Pathology Department British Columbia's Children's Hospital Vancouver BC Canada
Children's Center for Cancer and Blood Diseases Children's Hospital Los Angeles Los Angeles CA USA
Department of Epidemiology and Cancer Control St Jude Children's Research Hospital Memphis TN USA
Department of Oncology St Jude Children's Research Hospital Memphis TN USA
Department of Otolaryngology Stanford University Palo Alto CA USA
Department of Pediatric and Adolescent Oncology Perth Children's Hospital Nedlands WA Australia
Department of Pediatrics and Adolescent Medicine Kepler Universitätsklinikum Linz Austria
Department of Pediatrics Children's University Hospital of Bern University of Bern Bern Switzerland
Department of Pediatrics Louisiana State University Health Sciences Center New Orleans LA USA
Division of Pediatric Hematology Oncology Children's Hospital of New Orleans New Orleans LA USA
Division of Pediatric Hematology Oncology University for Children's Hospital Basel Basel Switzerland
Great Ormond Street Hospital for Children NHS Foundation Trust London UK
Institute of Epidemiology and Preventive Medicine University of Regensburg Regensburg Germany
Keck School of Medicine University of Southern California Los Angeles CA USA
Kids Cancer Centre Sydney Children's Hospital High Street Randwick NSW Australia
Pediatric Oncology and Hematology University Hospital for Children and Adolescents Lübeck Germany
Pharmaceutical Outcomes Programme British Columbia's Children's Hospital Vancouver BC Canada
Princess Máxima Center for Pediatric Oncology Utrecht Netherlands
Rehabilitation Services St Jude Children's Research Hospital Memphis TN USA
School of Audiology and Speech Sciences University of British Columbia Vancouver BC Canada
School of Medicine University of Western Australia Perth WA Australia
School of Women's and Children's Health University of New South Wales Medicine Sydney NSW Australia
University of Lille CHU Lille Otology and Otoneurology Lille France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022952
- 003
- CZ-PrNML
- 005
- 20201214125024.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(18)30858-1 $2 doi
- 035 __
- $a (PubMed)30614474
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Clemens, Eva $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands.
- 245 10
- $a Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium / $c E. Clemens, MM. van den Heuvel-Eibrink, RL. Mulder, LCM. Kremer, MM. Hudson, R. Skinner, LS. Constine, JK. Bass, CE. Kuehni, T. Langer, EC. van Dalen, E. Bardi, NX. Bonne, PR. Brock, B. Brooks, B. Carleton, E. Caron, KW. Chang, K. Johnston, K. Knight, PC. Nathan, E. Orgel, PK. Prasad, J. Rottenberg, K. Scheinemann, ACH. de Vries, T. Walwyn, A. Weiss, A. Am Zehnhoff-Dinnesen, RJ. Cohn, W. Landier, International Guideline Harmonization Group ototoxicity group,
- 520 9_
- $a Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 12
- $a přežívající onkologičtí pacienti $x statistika a číselné údaje $7 D000073116
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a kraniální ozáření $x škodlivé účinky $7 D016371
- 650 _2
- $a poskytování zdravotní péče $x normy $7 D003695
- 650 _2
- $a medicína založená na důkazech $7 D019317
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x farmakoterapie $x radioterapie $7 D009369
- 650 _2
- $a ototoxicita $x diagnóza $x etiologie $x prevence a kontrola $x terapie $7 D000081015
- 650 _2
- $a sloučeniny platiny $x škodlivé účinky $7 D017671
- 650 _2
- $a surveillance populace $7 D011159
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a van den Heuvel-Eibrink, Marry M $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
- 700 1_
- $a Mulder, Renée L $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
- 700 1_
- $a Kremer, Leontien C M $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
- 700 1_
- $a Hudson, Melissa M $u Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.
- 700 1_
- $a Skinner, Roderick $u Department of Pediatric and Adolescent Hematology/Oncology and Children's Hematopoietic Stem Cell Transplant Unit, Great North Children's Hospital and Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
- 700 1_
- $a Constine, Louis S $u Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, New York, NY, USA.
- 700 1_
- $a Bass, Johnnie K $u Rehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA.
- 700 1_
- $a Kuehni, Claudia E $u Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Department of Pediatrics, Children's University Hospital of Bern, University of Bern, Bern, Switzerland.
- 700 1_
- $a Langer, Thorsten $u Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
- 700 1_
- $a van Dalen, Elvira C $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
- 700 1_
- $a Bardi, Edith $u Department of Pediatrics and Adolescent Medicine, Kepler Universitätsklinikum, Linz, Austria.
- 700 1_
- $a Bonne, Nicolas-Xavier $u University of Lille, CHU Lille, Otology and Otoneurology, Lille, France.
- 700 1_
- $a Brock, Penelope R $u Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
- 700 1_
- $a Brooks, Beth $u Rehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA; Audiology and Speech Pathology Department, British Columbia's Children's Hospital, Vancouver, BC, Canada; School of Audiology and Speech Sciences, University of British Columbia, Vancouver, BC, Canada.
- 700 1_
- $a Carleton, Bruce $u Pharmaceutical Outcomes Programme, British Columbia's Children's Hospital, Vancouver, BC, Canada; Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- 700 1_
- $a Caron, Eric $u Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.
- 700 1_
- $a Chang, Kay W $u Department of Otolaryngology, Stanford University, Palo Alto, CA, USA.
- 700 1_
- $a Johnston, Karen $u Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia.
- 700 1_
- $a Knight, Kristin $u Department of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, USA.
- 700 1_
- $a Nathan, Paul C $u Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
- 700 1_
- $a Orgel, Etan $u Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
- 700 1_
- $a Prasad, Pinki K $u Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Division of Pediatric Hematology/Oncology, Children's Hospital of New Orleans, New Orleans, LA, USA.
- 700 1_
- $a Rottenberg, Jan $u Department of Otolaryngology and Head and Neck Surgery, St Ann's University Hospital Brno, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Scheinemann, Katrin $u Division of Pediatric Hematology/Oncology, Hospital for Children and Adolescents, Cantonal Hospital Aarau, Aarau, Switzerland; Division of Pediatric Hematology/Oncology, University for Children's Hospital Basel, Basel, Switzerland; Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
- 700 1_
- $a de Vries, Andrica C H $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands.
- 700 1_
- $a Walwyn, Thomas $u Department of Pediatric and Adolescent Oncology, Perth Children's Hospital, Nedlands, WA, Australia; School of Medicine, University of Western Australia, Perth, WA, Australia.
- 700 1_
- $a Weiss, Annette $u Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
- 700 1_
- $a Am Zehnhoff-Dinnesen, Antoinette $u Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University of Münster, Münster, Germany.
- 700 1_
- $a Cohn, Richard J $u Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia; School of Women's and Children's Health, University of New South Wales Medicine, Sydney, NSW, Australia.
- 700 1_
- $a Landier, Wendy $u Institute for Cancer Outcomes and Survivorship, Department of Pediatrics, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, AL, USA. Electronic address: wlandier@peds.uab.edu.
- 710 2_
- $a International Guideline Harmonization Group ototoxicity group
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 20, č. 1 (2019), s. e29-e41
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30614474 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125024 $b ABA008
- 999 __
- $a ok $b bmc $g 1595271 $s 1113628
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 1 $d e29-e41 $e - $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- GRA __
- $a P30 CA014089 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 CA021765 $p NCI NIH HHS $2 United States
- GRA __
- $a U10 CA180886 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20201125
